Talk Bio – Page 51 – Actionable Insights Powered by AI

Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push

3 months ago talkbio0Tagged Billion, Biopharma, Fujifilm, Investments, Johnson and Johnson, Manufacturing, North Carolina, Surgical construction, U.S.

Johnson & Johnson; Fujifilm; manufacturing; North Carolina; $2 billion investment; biopharma; job creation; US manufacturing

Gilead’s Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

3 months ago talkbio0Tagged Acquisition, CAR-T, CAR-T therapy, Cell Therapy, Gilead, in vivo, Interius BioTherapeutics, Kite, device (physical object), Tecartus, Yescarta

Gilead; Kite; Interius BioTherapeutics; CAR-T therapy; in vivo CAR-T; acquisition; off-the-shelf cell therapy; $350 million; biotech; Yescarta; Tecartus; cell therapy platform

AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials

3 months ago talkbio0Tagged AbbVie, Alopecia, Eyebrow structure, Eyelash, hair regrowth, Rinvoq, safety profile, Salts, Score, upadacitinib

AbbVie; Rinvoq; upadacitinib; alopecia areata; Phase 3 clinical trial; hair regrowth; SALT score; eyebrows; eyelashes; safety profile

Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix

3 months ago talkbio0Tagged aspects of adverse effects, Dynavax, Effectiveness, Herpes zoster disease, Immunogenicity (package insert), Shingrix, Vaccines, Z-1018

Dynavax; Z-1018; shingles vaccine; Shingrix; vaccine efficacy; side effects; Phase 1/2 trial; immunogenicity

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

3 months ago talkbio0Tagged drug price, EU, generics, Nation, Pharma, Policy, tariffs, Transplant Registry Unified Management Program

Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma

AbbVie’s Rinvoq Achieves Strong Phase 3 Results in Alopecia Areata, Clearing Key Efficacy Milestone

3 months ago talkbio0Tagged AbbVie, Alopecia, hair regrowth, Inhibitor, Janus kinase, Rinvoq, Salts, Score, upadacitinib

AbbVie; Rinvoq; Phase 3 trial; alopecia areata; hair regrowth; upadacitinib; SALT score; JAK inhibitor

Sarepta Extends $700M Debt to 2030, Adds Private Placement Amid Elevidys Uncertainty

3 months ago talkbio0Tagged Biopharma, convertible, debt maturity extension, ELEVIDYS, financial strategy, Note (document), private placement

Sarepta Therapeutics; debt maturity extension; convertible notes; private placement; Elevidys; financial strategy; biopharma

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

3 months ago talkbio0Tagged Appointments, biotech leadership, Cancer Therapeutic Procedure, CEO, Commissioner, Hahn, Nucleus RadioPharma, Radiopharmaceuticals, supply chain, United States Food and Drug Administration

Nucleus RadioPharma; Stephen Hahn; FDA Commissioner; CEO appointment; radiopharmaceuticals; cancer therapy; supply chain; biotech leadership

FDA Delays Decisions on Regeneron’s Eylea HD Due to Manufacturing Issues

3 months ago talkbio0Tagged Biosimilars, Deferred, Edema, Eylea HD, macular, manufacturing issues, Nordisk facility, Pre-filled Syringe, Regeneron, regulatory approval, Retinal Vein Occlusion, United States Food and Drug Administration

FDA delay; Regeneron; Eylea HD; manufacturing issues; Novo Nordisk facility; biosimilars; pre-filled syringe; macular oedema; retinal vein occlusion; regulatory approval

American Academy of Pediatrics Breaks with RFK Jr., CDC on COVID Vaccines for Kids

3 months ago talkbio0Tagged Academy of Pediatrics, antiarrhythmic peptide, Centers for Disease Control and Prevention (U.S.), Child, COVID19 (disease), Immunization, Pediatric brand name, Policy, public health guidance, Robert F. Kennedy, Vaccines

American Academy of Pediatrics; AAP; COVID-19 vaccine; children; CDC; Robert F. Kennedy Jr.; pediatric immunizations; public health guidance; vaccine policy